Current study also supports our hypothesis in a previous paper that a mutant CXCL10, without CXCR3-binding activity, delivered directly to the lungs could be a novel therapeutic agent in pulmonary fibrosis (5). The gene discussed is CXCR3; the disease is pulmonary fibrosis.